Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris Inc. (VTRS) has appointed Hemanth J. Varghese as Chief Strategy Officer, joining the Company's Executive Leadership Team. Varghese brings over 20 years of experience in strategy, operations, and corporate development within healthcare companies.
Prior to this appointment, Varghese served as President and COO at Venus Concept, SVP of Strategy & Operations at HLS Therapeutics, and held executive positions at Endo International, Valeant Pharmaceuticals, and Bausch & Lomb. He holds a bachelor's degree and Ph.D. in medical biophysics from the University of Western Ontario and is a Chartered Financial Analyst.
CEO Scott A. Smith expressed confidence that Varghese's expertise will be important for Viatris's growth strategy in 2026 and beyond.
Viatris (VTRS) has announced a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes. The settlement, which does not admit wrongdoing or liability, requires the company to pay up to $335 million over nine years, with annual payments ranging between $27.5 and $40 million.
The company had previously accounted for this potential settlement in its 2024 Form 10-K. Viatris, which has a minimal presence in the U.S. opioids market, manufactures generic versions of naloxone (overdose reversal drug) and buprenorphine/naloxone (opioid addiction treatment). The company is also developing a novel delivery system for meloxicam, a non-opioid pain medication.
Viatris (NASDAQ: VTRS) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. ET on the same day to discuss the quarterly performance.
Interested investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website.
Viatris (NASDAQ: VTRS) has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL. The healthcare company will conduct a fireside chat on Tuesday, March 11, 2025 at 2 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available at the same location for a time following the event.
Viatris (VTRS) reported its Q4 and full-year 2024 results, meeting guidance for revenues, adjusted EBITDA, and EPS while exceeding free cash flow targets. The company achieved $14.7 billion in total revenues, with a U.S. GAAP net loss of $(634) million and adjusted EBITDA of $4.7 billion.
Key highlights include $582 million in new product revenues, $825 million returned to shareholders, and $3.7 billion in debt repayment. The company faces challenges with its Indore facility, expecting a negative impact of ~$500 million on 2025 revenues and ~$385 million on adjusted EBITDA due to FDA warning letter and import alert.
For 2025, Viatris plans to prioritize capital return with $500-650 million in share repurchases and expects six Phase 3 data readouts for key assets including selatogrel, cenerimod, and sotagliflozin.
Viatris (NASDAQ: VTRS) has announced its dividend policy for 2025, maintaining an annual dividend of $0.48 per share. The company's Board of Directors has declared a quarterly dividend of $0.12 per share, payable on March 18, 2025, to shareholders of record as of March 10, 2025. This represents the company's fifth consecutive year of dividend payments, demonstrating continued commitment to shareholder returns.
Viatris Inc. (NASDAQ: VTRS) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The company will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website.
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's presentation and fireside chat are scheduled for Tuesday, January 14, 2025, at 8:15 a.m. PT / 11:15 a.m. ET.
Investors and interested parties can access a live webcast of the event through investor.viatris.com. An archived version of the presentation will be made available at the same location for a time following the live event.
Viatris (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results for cenerimod in treating moderate-to-severe systemic lupus erythematosus (SLE). Published in Lancet Rheumatology, the study showed that cenerimod 4 mg demonstrated meaningful improvement in SLE disease activity compared to placebo. The trial involved 427 patients aged 18-75 years, randomized across different dosage groups.
Key findings include a -4.04 change from baseline in mSLEDAI-2K score for the 4 mg group, with stronger results in patients with high IFN-1 gene expression. The drug was well-tolerated with mostly mild to moderate adverse events. Additional biomarker data published in the Annals of the Rheumatic Diseases further characterized cenerimod's mechanism of action. These results have informed the ongoing Phase 3 OPUS program.
Viatris (VTRS) reported Q3 2024 financial results with total revenues of $3.8 billion and operational revenue growth of ~3% on a divestiture-adjusted basis. Key highlights include new product revenues of $133 million, U.S. GAAP net earnings of $95 million, and adjusted EBITDA growth of ~4% to $1.3 billion. The company repaid ~$1.9 billion of debt and expects to achieve its long-term gross leverage target of ~3.0x by year-end. Viatris entered an exclusive licensing agreement for sotagliflozin, expanding its cardiovascular disease portfolio. The company reaffirms its 2024 full-year outlook, expecting revenue growth of ~2% on a divestiture-adjusted operational basis.